HAEMA BLUT UND PLASMA
LIVE

Serial Number

79411781

Owner

Haema GmbH

Attorney

Deborah L. Shapiro

Filing Date

Jul 4, 2024

Add to watchlist:

No watchlists yet
View on USPTO

HAEMA BLUT UND PLASMA Trademark

Serial Number: 79411781 • Registration: 8105646

HAEMA BLUT UND PLASMA is a trademark filed by Haema GmbH on July 4, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

Haema GmbH (13 trademarks)

Landsteinerstraße 1

Entity Type: 98

Haema AG (13 trademarks)

Deutscher Platz 5e

Entity Type: 98

Trademark Details

Filing Date

July 4, 2024

Registration Date

January 20, 2026

Published for Opposition

December 2, 2025

Goods & Services

Updating and maintenance of blood donor data in computer databases

Technical provision and support for data processing systems, namely, providing technology information in the field of data processing and technical support services in the nature of troubleshooting computer software problems in connection with data processing; providing temporary use of online non-downloadable computer software for accessing patient treatment databases and donor databases; providing technological and scientific information about scientific laboratories services and blood banks, in particular medical laboratories; providing scientific information derived from analysis of medical diagnostic results; blood analysis services for scientific research purposes; scientific laboratory services; chemical laboratories and medical research laboratories; scientific research in the field of physics; chemistry services, namely, chemical analysis, chemical laboratories; chemical analysis; scientific testing services, namely, blood testing for scientific research purposes; blood testing for scientific research purposes, with said testing entailing filtration, separation and centrifugation of blood; laboratory trials, namely, medical and scientific research in the nature of conducting clinical trials for others; development and further development of data processing computer software and hardware in the field of laboratory medicine and blood and plasma collection; database development services, namely, creation of medical databases in digital form; scientific and medical research in the medical and pharmaceutical fields; scientific and medical research in the field of chemistry and biology; development and establishment of testing specifications and procedures for the medical industry, namely, development of medical equipment procedures and test procedures, donation procedures and medical instrument procedures

Medical analysis services and medical consultancy all relating to the treatment of persons in connection with blood and plasma donation; medical consultancy in relation to transfusion medicine; pharmacy advice in the nature of pharmaceutical advice; providing of medical information in relation to blood donation centres; providing of medical and pharmaceutical support being medical assistance and pharmaceutical advice via telephone; medical services in the field of blood fractionation and treatment; medical services in the field of blood sampling and collection; blood testing services being medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical assistance; blood bank services; blood donation centres being health center services; blood extraction stations being health center services; medical services in the field of immunotherapy; medical consultancy in relation to transfusion medicine and clinic hygiene; medical transfusion consultancy in clinics, in particular medical consultancy by doctors administering transfusions; medical transfusion testing for diagnostic or treatment purposes; providing medical diagnostic information through medical results; medical diagnostic services within the framework of conducting medical examinations; conducting of blood donation, platelet donation, erythrocyte donation, whole blood donation, plasma donation, and autologous donation, all in the nature of blood bank services; medical examination services; execution of clinical examination services, namely, medical examination services; dietetic advisory services; medical services in the nature of providing medical opinions; health counselling; medical services in the field of transfusion and transplantation of blood and blood components; medical services; providing medical information relating to the use of medical equipment, instruments and apparatus for medical purposes; medical services relating to packed red blood cell banks; medical services relating to platelet concentrate banks; medical services relating to leukocyte banks; medical services relating to blood plasma banks, and blood for medical and diagnostic purposes; blood component banks being blood bank services; health assessment services, namely, providing a database in the field of blood donor medical information based on collected data and information all for treatment and diagnostic purposes; extraction of stem cells being medical services relating to the removal, treatment and processing of stem cells

Medicines, in particular medicines made from blood components, fractions and preparations, with said medicines being for the treatment of diseases and disorders of the blood; blood components, fractions and preparations, namely, blood for medical purposes, blood plasma, and blood substitutes for human use; blood components, fractions and preparations for injection, namely, blood for medical purposes, blood plasma, and blood substitutes for human use; blood components, fractions and preparations for automatic transplantation, namely, blood for medical purposes, blood plasma, and blood substitutes for human use; blood components, fractions and preparations for transfusion, namely, blood for medical purposes, blood plasma, and blood substitutes for human use; blood components, fractions and preparations for immunotherapy, namely, blood for medical purposes, blood plasma, and blood substitutes for human use; blood components, fractions and preparations for autologous transfusion, namely, blood for medical purposes, blood plasma, and blood substitutes for human use; blood, blood fractions and blood components for medical, therapeutic and prophylactic purposes, namely, blood for medical purposes, blood plasma, and blood substitutes for human use; blood plasma; cells for medical use, namely, blood cell preparations; health care substances and preparations, in particular for haematology, namely, pharmaceuticals for the treatment of blood diseases and disorders, blood for medical purposes, blood plasma, and blood substitutes for human use; finished medical products, namely, blood for human use and blood plasma; preparations for medical purposes, in particular haematology preparations, namely, pharmaceuticals for the treatment of blood diseases and disorders, blood for medical purposes, blood plasma, and blood substitutes for human use; immunotherapeutic and immunoprophylactic preparations, namely, pharmaceuticals for treating immunological diseases and disorders; living cells for medical purposes, namely, leukocyte preparations of white blood cells; Living cells and cell fragments for medical purposes, namely, platelet and red blood cell concentrates; blood plasma, namely, quarantine plasma and fractionated plasma; clinical medical reagents for processing human blood and blood components for use in blood transfusions and for extracorporeal blood processing stored in bags, bottles, syringes and similar containers for storing substances such as these for medical purposes; pharmaceutical products and haematology preparations for the treatment of blood and blood components, in particular infusion and transfusion solutions in the nature of blood, blood plasma, and blood substitutes for human use and pharmaceuticals for the treatment of blood diseases and disorders; pharmaceutical blood plasma preparations for the treatment of blood diseases and disorders; pharmaceutical blood preparations for the treatment of blood diseases and disorders; pharmaceutical blood products, namely, pharmaceuticals for the treatment of blood diseases and disorders; cell material for autotransplantation and autotransfusion, namely, cells for medical use; cell material for transplantation and transfusion, namely, cells for medical use; cell material for medical, therapeutic and prophylactic purposes, namely, cells for medical or clinical use

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Aug 13, 2026 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jul 27, 2026 FICS
FINAL DISPOSITION PROCESSED
Jul 27, 2026 FIMP
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
May 28, 2026 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
May 11, 2026 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
May 11, 2026 OPNR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Apr 20, 2026 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jan 20, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Jan 20, 2026 R.PR
NOTIFICATION PROCESSED BY IB
Dec 11, 2025 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 2, 2025 NPUB
PUBLISHED FOR OPPOSITION
Dec 2, 2025 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Nov 26, 2025 OPNS
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 26, 2025 NONP
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Nov 25, 2025 OP2R
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 31, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Oct 31, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Oct 31, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Oct 31, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Oct 31, 2025 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 30, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 30, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 30, 2025 TROA
REFUSAL PROCESSED BY IB
Sep 27, 2025 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sep 5, 2025 RFCS
REFUSAL PROCESSED BY MPU
Sep 5, 2025 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Aug 1, 2025 RFCR
NON-FINAL ACTION WRITTEN
Jul 31, 2025 CNRT
ASSIGNED TO EXAMINER
Jul 31, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
Jul 30, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 30, 2025 NWOS
CHANGE OF NAME/ADDRESS REC'D FROM IB
Apr 18, 2025 ADCH
SN ASSIGNED FOR SECT 66A APPL FROM IB
Dec 12, 2024 REPR